Clinical trial
Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
NCT03451045 · Corbus Pharmaceuticals Inc., Industry · Completed
Key facts
| NCT number | NCT03451045 |
|---|---|
| Title | Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis |
| Lead sponsor | Corbus Pharmaceuticals Inc., Industry |
| Collaborators | Cystic Fibrosis Foundation |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis |
| Intervention type | Drug, Other |
| Interventions | Lenabasum 20 mg, Lenabasum 5 mg, Placebo |
| Enrollment | 447 |
| Start date | Dec 22, 2017 |
| Primary completion | Jun 17, 2020 |
| Completion | Jun 17, 2020 |
| First posted | Mar 1, 2018 |
| Last update posted | Jan 18, 2023 |
| Countries | Austria, Belgium, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Italy, Netherlands, Poland and 9 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: